Evolent Health (EVH) Cash & Equivalents (2015 - 2026)

Evolent Health has reported Cash & Equivalents for 12 years, with the latest figure at $115.7 million in Q2 2026.

• On a quarterly basis, Cash & Equivalents fell 23.37% year-over-year to $115.7 million in Q2 2026; TTM through Jun 2026 was $115.7 million, a 23.37% decrease from a year earlier, with the FY2025 full-year figure at $151.9 million, up 45.73% from the prior year.
• Cash & Equivalents was $115.7 million for Q2 2026 at Evolent Health, down from $142.0 million in the prior quarter.
• The five-year high for Cash & Equivalents was $246.5 million in Q1 2025, with the low at $96.6 million in Q3 2024.
• Average Cash & Equivalents over 5 years is $156.5 million, with a median of $154.3 million recorded in 2022.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents slumped 47.66% in 2024, then soared 49.29% in 2025.
• Over 5 years, Cash & Equivalents stood at $188.2 million in 2022, then grew by 2.46% to $192.8 million in 2023, then slumped by 45.96% to $104.2 million in 2024, then soared by 45.73% to $151.9 million in 2025, then fell by 23.81% to $115.7 million in 2026.
• The last three Cash & Equivalents figures came in at $115.7 million (Q2 2026), $142.0 million (Q1 2026), and $151.9 million (Q4 2025), per Business Quant data.